IKT News and Press, Inhibikase Therapeutics Inc. From 04/01/21

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity PR Newswire ATLANTA , April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company...

Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference PR Newswire ATLANTA , Mar. 2, 2021 /PRNewswire/ --&...

Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference Therapeutic outcome data for oral IkT-148009 demonstrated inhibition of the Abelson Tyrosine Kinase c-Abl may lead to functional recovery PR Newswire ATL...

Inhibikase Therapeutics (IKT) announces dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.The randomized Phase 1 study is investigating the safety, tolerability and pharmaco...

- IKT-148009 is a mechanistically defined disease-modifying therapy - Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today ann...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The Q4 earnings season cranks up with Procter & Gamble (NYSE:PG), Netflix (NASDAQ:NFLX) and Intel (NASDAQ:INTC) some...

Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China's leading e-cigarette brand RLX Technology plans to raise $1.0 billion at a $14.0 billion market cap. Street research is expected for Inhibikase Therape...

Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer PR Newswire ATLANTA , Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a c...